A review on oxaliplatin-induced peripheral nerve damage.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Treatment Reviews

• Publication date

  2008-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ctrv.2008.01.003PMID 18281158
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recent Advances in the Pharmacological Management of Pain

  2012cited by this paper
• Antiepileptic Drugs in the Treatment of Neuropathic Pain

  2012cited by this paper
• Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer

  2008cited by this paper
• FOLFOX-4 Stop and Go and Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer

  2007cited by this paper
• The emerging diversity of neuromuscular junction disorders.

  2007cited by this paper
• Mitochondria and neuronal activity.

  2007cited by this paper
• Oxidative stress and the pathogenesis of neurodegenerative disorders.

  2007cited by this paper
• Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.

  2007cited by this paper
• The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity Scale

  2007cited by this paper
• Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity.

  2007cited by this paper
• Oxaliplatin in the treatment of colorectal cancer

  2007cited by this paper
• Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer

  2007cited by this paper
• Highlights From: the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA, January 2006.

  2006cited by this paper
• Oxaliplatin-related neurotoxicity: how and why?

  2006cited by this paper
• OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.

  2006cited by this paper
• OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

  2006cited by this paper
• Pharmacological strategies for the prevention of Alzheimer’s disease

  2006cited by this paper
• Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy

  2006cited by this paper
• Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study

  2006cited by this paper
• Xaliproden lessens oxaliplatin-mediated neuropathy.

  2006cited by this paper
• Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.

  2006cited by this paper
• Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer.

  2006cited by this paper
• Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.

  2006cited by this paper
• Clinical management of oxaliplatin-associated neurotoxicity.

  2005cited by this paper
• Editorial [Hot Topic: Anti-Cancer Drugs Executive Editor: Elke Bergmann-Leitner]

  2005cited by this paper
• Oxaliplatin‐induced neurotoxicity and the development of neuropathy

  2005cited by this paper
• Advances in the treatment of metastatic colorectal cancer.

  2005cited by this paper
• Analysis of cytotoxicities of platinum compounds

  2005cited by this paper
• A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: A North Central Cancer Treatment Group study

  2005cited by this paper
• How chest CT for the diagnosis of pulmonary embolism (PE) has changed my professional life: reflections from a PE doctor.

  2005cited by this paper
• Oxaliplatin-Associated Neuropathy: A Review

  2005cited by this paper
• Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs.

  2005cited by this paper
• Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?

  2005cited by this paper
• Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.

  2005cited by this paper
• Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy.

  2005cited by this paper
• What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?

  2004cited by this paper
• Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies

  2004cited by this paper
• Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions

  2004cited by this paper
• Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.

  2004cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• Oxaliplatin‐induced neurotoxicity: Acute hyperexcitability and chronic neuropathy

  2004cited by this paper
• A review of oxaliplatin and its clinical use in colorectal cancer

  2004cited by this paper
• Progressive paresthesias after cessation of therapy with very high-dose cisplatin

  2004cited by this paper
• FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

  2004cited by this paper
• Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

  2003cited by this paper
• Toxicity of platinum compounds

  2003cited by this paper
• Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale

  2003cited by this paper
• Toxicities of the platinum antineoplastic agents

  2003cited by this paper
• Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.

  2002cited by this paper
• Acute oxaliplatin-induced peripheral nerve hyperexcitability.

  2002cited by this paper
• Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

  2002cited by this paper
• Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid.

  2002cited by this paper
• [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].

  2002cited by this paper
• Exacerbation of oxaliplatin neurosensory toxicity following surgery.

  2002cited by this paper
• Lhermitte sign and urinary retention

  2002cited by this paper
• The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.

  2002cited by this paper
• Chemotherapy-induced peripheral neuropathy

  2002cited by this paper
• Recent advances in drug-induced neuropathies

  2002cited by this paper
• A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.

  2001cited by this paper
• Oxaliplatin: available data in non-colorectal gastrointestinal malignancies.

  2001cited by this paper
• High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

  2001cited by this paper
• Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy.

  2001cited by this paper
• Amifostine: chemotherapeutic and radiotherapeutic protective effects

  2001cited by this paper
• Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat.

  2001cited by this paper
• Clinical pharmacokinetics of oxaliplatin: a critical review.

  2000cited by this paper
• The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons.

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs

  2000cited by this paper
• Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

  1999cited by this paper
• Total neuropathy score

  1999cited by this paper
• Comparative Anticonvulsant and Mechanistic Profile of the Established and Newer Antiepileptic Drugs

  1999cited by this paper
• Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

  1998cited by this paper
• Pharmacokinetics and safety profile of oxaliplatin.

  1998cited by this paper
• Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.

  1998cited by this paper
• Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

  1998cited by this paper
• Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model.

  1998cited by this paper
• Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.

  1996cited by this paper
• Repetitive CMAPs: Mechanisms of neural and synaptic genesis

  1996cited by this paper
• Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

  1996cited by this paper
• Comprehensive criteria for assessing therapy-induced toxicity.

  1990cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• Oxaliplatin-artesunate conjugate intensifies suppression on colorectal cancer by boosting antitumor immunity.

  2026cites this paper
• DRG Explant Model for Understanding Mechanism of Oxaliplatin-Induced Peripheral Neuropathy and Identifying Potential Therapeutic Targets.

  2026cites this paper
• Investigating the Effect of Oxaliplatin on Vesicular Dopamine Cargo and Release Dynamics in Brain with Single-Vesicle Electrochemistry.

  2026cites this paper
• Cistanche tubulosa phenylethanol glycoside liposome ameliorates oxaliplatin-induced peripheral neuropathy by promoting RNA N6-methyladenosine modification.

  2026cites this paper
• Rational design, biological and in-silico evaluation of quinoline-chalcone hybrids: A new series of antimicrobial and anticancer agents

  2025cites this paper
• Modeling of Pressure Control in Compressive Gloves for Neuropathy Prevention

  2025cites this paper
• Central vs. Peripheral Venous Oxaliplatin Administration and Chemotherapy-Induced Peripheral Neuropathy Severity.

  2025cites this paper
• Cilastatin Modulates DPEP1- and IQGAP1-Associated Neuro-Glio-Vascular Inflammation in Oxaliplatin-Induced Peripheral Neurotoxicity

  2025cites this paper
• Sense-checking the approach to quantitative sensory testing to detect chemotherapy-induced peripheral neuropathy

  2025cites this paper
• Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs

  2025cites this paper
• Current Chemotherapy Strategies for Colorectal Cancer: Challenges and Future Directions

  2025cites this paper
• Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuro-pathy: a cross-sectional cohort study

  2025cites this paper
• A Targeted Redox‐Active Dual‐Action Pt(IV)‐Mn(II) Prodrug Displays Enhanced In Vivo Anticancer Activity

  2025cites this paper
• Effectiveness of Statins for Oxaliplatin‐Induced Peripheral Neuropathy: A Multicenter Retrospective Observational Study

  2025cites this paper
• Organotin(IV)-tetraphenylethylene acylhydrazone compounds with aggregation-induced emission property and application in anticancer therapy

  2024cites this paper
• Role of miRNA-181a in the Treatment of Oxaliplatin-Induced Neuropathy with Asprosin: An Examination in Mouse Dorsal Root Ganglia

  2024cites this paper
• Mu-Opioid Receptor (MOR) Dependence of Pain in Chemotherapy-Induced Peripheral Neuropathy

  2024cites this paper
• Water-Soluble Fluorescent Sensors for Quantification of Trace Cisplatin in Body Fluids from Clinical Cancer Patients.

  2024cites this paper
• The Association between Oxaliplatin-Induced Peripheral Neuropathy, Sociodemographic, and Clinical Characteristics with Falls in Older Adults with Colorectal Cancer.

  2024cites this paper
• Assessment of orofacial nociceptive behaviors of mice with the sheltering tube method: Oxaliplatin-induced mechanical and cold allodynia in orofacial regions

  2024cites this paper
• Quantitative orbital tightening for pain assessment using machine learning with DeepLabCut

  2024cites this paper
• Subcutaneous administration of a novel TRPM8 antagonist reverses cold hypersensitivity while attenuating the drop in core body temperature

  2024cites this paper
• Targeted Delivery of Oxaliplatin to Colorectal Cancer Using the Cancer-Specific Cell-Penetrating Peptide BR2

  2024cites this paper
• Albumin Nanoparticle Enhances Oxaliplatin Concentration in the Colorectal Region to Treat Colon Cancer with Increased Efficacy

  2024cites this paper
• Design, Synthesis, and Toxicity Evaluation of the Green Synthesized Oxaliplatin Nanoparticles Using Ginger Extract against Colorectal Cancer Cells

  2024cites this paper
• Oxaliplatin-induced transient ischemic attack (TIA): A rare presentation.

  2024cites this paper
• Post-marketing surveillance of anticancer drugs using natural language processing of electronic medical records

  2024cites this paper
• Near-Infrared Visualization of NAD(P)H Dynamics in Live Cells and Drosophila melanogaster Larvae Using a Coumarin-Based Pyridinium Fluorescent Probe.

  2024cites this paper
• A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system

  2023cites this paper
• Synthesis, Characterization, and Anticancer Activity of Phosphanegold(i) Complexes of 3-Thiosemicarbano-butan-2-one Oxime

  2023cites this paper
• DRG Explant Model: Elucidating Mechanisms of Oxaliplatin-Induced Peripheral Neuropathy and Identifying Potential Therapeutic Targets

  2023cites this paper
• Acovenoside A as a novel therapeutic approach to boost taxol and carboplatin apoptotic and antiproliferative activities in NSCLC: Interplay of miR-630/miR-181a and apoptosis genes.

  2023cites this paper
• Evaluation of neurotoxicity of anticancer drugs using nematode Caenorhabditis elegans as a model organism.

  2023cites this paper
• The neuroprotective effect of pterostilbene on oxaliplatin-induced peripheral neuropathy via its anti-inflammatory, anti-oxidative and anti-apoptotic effects: Comparative study with celecoxib.

  2023cites this paper
• Biomedical and clinical applications of platinum-based nanohybrids: An update review.

  2023cites this paper
• Oxaliplatin causes increased offset analgesia during chemotherapy – a feasibility study

  2023cites this paper
• From Basics of Coordination Chemistry to Understanding Cisplatin-analogue Pt Drugs.

  2023cites this paper
• Chalcones: An insight into their anticancer potential and action mechanism

  2023cites this paper
• Broad-spectrum neuroprotection exerted by DDD-028 in a mouse model of chemotherapy-induced neuropathy

  2023cites this paper
• Comparative assessment of clinical trials, indications, pharmacokinetic parameters and side effects of approved platinum drugs

  2022cites this paper
• Comparative Analysis of Clinical Trials, Therapeutic Uses, Pharmacokinetics, and Adverse Effects of Approved Platinum-Based Drugs

  2022cites this paper
• Natural Polyphenols-Platinum Nanocomplexes Stimulate Immune System for Combination Cancer Therapy.

  2022cites this paper
• Duloxetine alleviates oxaliplatin-induced peripheral neuropathy by regulating p53-mediated apoptosis

  2022cites this paper
• Exacerbation of Cisplatin Cellular Toxicity by Regulation of the Human Organic Cation Transporter 2 through Angiotensin II

  2022cites this paper
• Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric Cancer

  2022cites this paper
• In vitro and In vivo Studies of Potential Anticancer Agents of Platinum(II) Complexes of Dicyclopentadiene and Dithiocarbamates.

  2022cites this paper
• Functional imaging and targeted drug delivery in mice and patient tumors with a cell nucleolus-localizing and tumor-targeting peptide.

  2022cites this paper
• Utilizing network pharmacological analysis to investigate the key targets and mechanisms of kaempferol against oxaliplatin-induced neurotoxicity

  2022cites this paper
• An AIE-featured triphenyltin(IV)-triphenylamine acylhydrazone compound and anticancer application

  2022cites this paper
• New organoruthenium(II) complexes containing N, X-donor (X = O, S) heterocyclic chelators: Synthesis, spectral characterization, in vitro cytotoxicity and apoptosis investigation

  2022cites this paper
• Potential Drug Interactions Between Psychotropics and Intravenous Chemotherapeutics Used by Patients With Cancer

  2022cites this paper
• New diagnostic measures of oxaliplatin-induced peripheral sensory neuropathy.

  2022cites this paper
• Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial

  2021influential citation
• Photobiomodulation Therapy Applied after 6 Months for the Management of a Severe Inferior Alveolar Nerve Injury

  2021cites this paper
• Efficacy Evaluation of Mirogabalin for Chemotherapy-induced Peripheral Neuropathy

  2021cites this paper
• Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial)

  2021cites this paper
• Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment

  2021cites this paper
• Drug-Induced Peripheral Neuropathy: Diagnosis and Management.

  2021cites this paper
• The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice

  2021cites this paper
• Natural History of Chemotherapy-Induced Peripheral Neuropathy

  2021cites this paper
• In vitro and in vivo combinatorial anticancer effects of oxaliplatin- and resveratrol-loaded N,O-carboxymethyl chitosan nanoparticles against colorectal cancer.

  2021cites this paper
• Assessment of Oxaliplatin and Carboplatin on Some Attributes of Cell Division in Lathyrus sativus L.

  2021cites this paper
• Epigenetics Involvement in Oxaliplatin-Induced Potassium Channel Transcriptional Downregulation and Hypersensitivity

  2021cites this paper
• Network Pharmacology and Experimental Evidence Identify the Mechanism of Astragaloside IV in Oxaliplatin Neurotoxicity

  2021cites this paper
• ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC)

  2021cites this paper
• Addressing the Need of a Translational Approach in Peripheral Neuropathy Research: Morphology Meets Function

  2021cites this paper
• Monofunctional Platinum(II) Anticancer Agents

  2021cites this paper
• Splenomegaly during oxaliplatin-based chemotherapy: impact on blood parameters and anti-neoplastic treatment

  2021cites this paper
• Small extracellular vesicles ameliorate peripheral neuropathy and enhance chemotherapy of oxaliplatin on ovarian cancer

  2021influential citation
• Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice

  2021cites this paper
• Chemotherapy-Induced Peripheral Neuropathy

  2020cites this paper
• Mesenchymal stem cells in chemotherapy‐induced peripheral neuropathy: A new challenging approach that requires further investigations

  2020cites this paper
• Triggering of Apoptosis in Osteosarcoma 143B Cell Line by Carbon Quantum Dots via the Mitochondrial Apoptotic Signal Pathway

  2020cites this paper
• Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing

  2020cites this paper
• Exploring the Promise of Flavonoids to Combat Neuropathic Pain: From Molecular Mechanisms to Therapeutic Implications

  2020cites this paper
• FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study

  2020cites this paper
• Syntheses, crystal structures, thermal stabilities, CT-DNA, and BSA binding characteristics of a new acylhydrazone and its Co(II), Cu(II), and Zn(II) complexes

  2020cites this paper
• The Incidence of Oxaliplatin-Induced Peripheral Neurotoxicity at Khartoum Oncology Hospital: A Cross-Sectional Survey

  2020cites this paper
• Chemotherapy-Induced Peripheral Neuropathy: Nursing Implications.

  2020cites this paper
• Development of highly potent Arene-Ru (II)-ninhydrin complexes for inhibition of cancer cell growth

  2020cites this paper
• Dose-Escalation and Pharmacokinetic Study Following a Single Dose of Oxaliplatin in Cancer-Bearing Dogs.

  2020cites this paper
• Synthesis, characterization, and antitumor activity of novel tumor‐targeted platinum(IV) complexes

  2020cites this paper
• Evaluating the Effects of Duloxetine on oxaliplatin Induced Peripheral Neuropathy Prophylaxis in Gastrointestinal Cancer Patients, randomized double-blind placebo controlled clinical Trial

  2020influential citation
• Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes.

  2020cites this paper
• Study on efficacy and safety of Huangqi Guizhi Wuwu decoction treatment for oxaliplatin induced peripheral neurotoxicity

  2020cites this paper
• Role of SLC transporters in toxicity induced by anticancer drugs

  2020cites this paper
• Electronic von Frey as an objective assessment tool for oxaliplatin-induced peripheral neuropathy: A prospective longitudinal study.

  2020cites this paper
• Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: A randomized, double blind, placebo-controlled, clinical trial

  2020cites this paper
• Acute chemotherapy-induced peripheral neuropathy due to oxaliplatin administration without cold stimulation

  2020cites this paper
• Effect of Oxaliplatin on Voltage-Gated Sodium Channels in Peripheral Neuropathic Pain

  2020cites this paper
• Qualitative Evaluation of the Influence of Acute Oxaliplatin‐Induced Peripheral Neuropathy on Quality of Life and Activities of Daily Life

  2020cites this paper
• Development and Validation of a New Evaluation Index for Oxaliplatin-Induced Cold Hypersensitivity Symptoms

  2020cites this paper
• Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.

  2020cites this paper
• Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice.

  2020cites this paper
• Development of Newly Synthesized Chromone Derivatives with High Tumor Specificity against Human Oral Squamous Cell Carcinoma

  2020cites this paper
• Platinum(II) Drug-Loaded Gold Nanoshells for Chemo-Photothermal Therapy in Colorectal Cancer.

  2020cites this paper
• Imbalanced Subthreshold Currents Following Sepsis and Chemotherapy: A Shared Mechanism Offering a New Therapeutic Target?

  2020cites this paper
• In Vitro and In Vivo Effects of Flavonoids on Peripheral Neuropathic Pain

  2020cites this paper
• Are Ergothioneine Levels in Blood Associated with Chronic Peripheral Neuropathy in Colorectal Cancer Patients Who Underwent Chemotherapy?

  2020cites this paper
• Treatment of Chronic Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review

  2020cites this paper